DIMENSION THERAPEUTICS INC (DMTX) Stock Price, Quote, News and Overview
NASDAQ:DMTX - Nasdaq - US25433V1052
DMTX Quote, Performance and Key Statistics
5.95
-0.02 (-0.42%)
The current stock price of DMTX is 5.95 null. In the past month the price decreased by -0.83%. In the past year, price increased by 3.48%.
About DMTX
Company Profile
Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.
Company Info
DIMENSION THERAPEUTICS INC
840 Memorial Drive
CAMBRIDGE MA 02139
CEO: Annalisa Jenkins
Phone: 617-401-0011
DIMENSION THERAPEUTICS INC / DMTX FAQ
What is the stock price of DIMENSION THERAPEUTICS INC today?
The current stock price of DMTX is 5.95 null. The price decreased by -0.42% in the last trading session.
What is the ticker symbol for DIMENSION THERAPEUTICS INC stock?
The exchange symbol of DIMENSION THERAPEUTICS INC is DMTX and it is listed on the Nasdaq exchange.
On which exchange is DMTX stock listed?
DMTX stock is listed on the Nasdaq exchange.
What is DIMENSION THERAPEUTICS INC worth?
DIMENSION THERAPEUTICS INC (DMTX) has a market capitalization of 150.00M null. This makes DMTX a Micro Cap stock.
What are the support and resistance levels for DIMENSION THERAPEUTICS INC (DMTX) stock?
DIMENSION THERAPEUTICS INC (DMTX) has a support level at 5.94 and a resistance level at 5.97. Check the full technical report for a detailed analysis of DMTX support and resistance levels.
Should I buy DIMENSION THERAPEUTICS INC (DMTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DMTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DMTX, evaluating the profitability, health, valuation and growth aspects
- DIMENSION THERAPEUTICS INC (DMTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DIMENSION THERAPEUTICS INC (DMTX) Sales and EPS estimates to see what analysts future expectations are.
- DIMENSION THERAPEUTICS INC (DMTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DIMENSION THERAPEUTICS INC (DMTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- DIMENSION THERAPEUTICS INC (DMTX) Stock Chart to make your own analysis
- DIMENSION THERAPEUTICS INC (DMTX) Latest news and press-releases to stay up to date.
Does DIMENSION THERAPEUTICS INC (DMTX) stock pay dividends?
DMTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of DIMENSION THERAPEUTICS INC (DMTX)?
DIMENSION THERAPEUTICS INC (DMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
DMTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DMTX. When comparing the yearly performance of all stocks, DMTX is one of the better performing stocks in the market, outperforming 99.2% of all stocks.
DMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMTX. Both the profitability and financial health of DMTX have multiple concerns.
DMTX Financial Highlights
Over the last trailing twelve months DMTX reported a non-GAAP Earnings per Share(EPS) of -2.2305. The EPS decreased by -364.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -336% | ||
| ROA | -111.28% | ||
| ROE | -274.1% | ||
| Debt/Equity | 0.14 |